Foster Announces 348 New Jobs and £54 Million Investment by Almac Group
Enterprise, Trade and Investment Minister Arlene Foster has announced that the Almac Group is investing over £54 million and creating 348 high quality jobs over the next 5 years.
The Almac Group operates in the pharmaceutical and biotechnology sectors providing services including drug discovery, diagnostics, research and development, manufacture of active pharmaceutical ingredients, formulation development and clinical trials.
It employs more than 2100 staff at its headquarters in Craigavon, with an additional 1380 staff located in facilities throughout the rest of the UK, US and Asia. The investment, supported by Invest Northern Ireland, relates to two of the Group’s operating business units, Pharma Services and Clinical Services.
Announcing the investment, Arlene Foster said: “Almac is one of Northern Ireland’s most successful indigenous companies and a globally respected brand. This significant investment will enable Almac to expand the range of services it can offer, allowing it to respond to key trends within the pharmaceutical industry and enhance its market-leading position.”
Almac Pharma Services provides contract development and manufacturing services to the world’s leading pharmaceutical and biotech companies. As well as recruiting 141 new staff over the next five years, the company will invest in new technologies and equipment to take advantage of the growing demand for outsourced development services.
Almac Clinical Services provides clinical packaging, labelling, logistics and clinical supply chain management services to the pharmaceutical industry. It is investing in cold chain storage and distribution facilities and enhanced information systems to capitalise on the demand from clients for closer partnering opportunities. The unit is creating 181 new jobs over the next 5 years.
The investments will also create a further 26 new jobs within the group.
“These 348 new jobs will generate salaries of over £9.4 million per annum when the projects are fully implemented. This is a significant cash injection for the local economy. The investments are also good news for our growing life sciences sector, which is gaining an international reputation for innovation and excellence,” added the Minister.
Invest NI has offered Almac Group £5.5 million of support towards its investment.
Alan Armstrong, Chairman and CEO of the Almac Group, said: “We are fortunate to employ an excellent highly-skilled workforce at our Craigavon headquarters which has played a major role in our global growth. It’s fantastic that demand for our services has resulted in the creation of so many new jobs as we embark on further expansion over the next 5 years.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance